Tagged with HE

USA Stephen J. Ubl, President & CEO of Pharmaceutical Research and Manufacturers of America (PhRMA) discusses the organisation’s initiatives to address health inequity in the US along with its opposition to the provisions in the Biden administration’s Build Back Better Act to lower costs and improve access. He also comments on…

Spain With global ambitions, Atrys Health, a publicly traded Spanish health-tech company, is betting on telediagnosis and last-generation radiotherapy to lead the precision medicine race, not missing the Big Data opportunities along the way. Its executive president, Dr. Santiago de Torres, explains why nothing is “too fast” when aiming for a…

USA When the FDA gave Novartis the historic green light for Kymriah – the first gene therapy approved in the United States – in 2017, the agency declared that it was “ushering in a new approach” to the treatment of cancer and other serious and life-threatening diseases. Today, more than 20…

Global At the recent Global Biopharma press briefing on COVID-19, held by the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), industry leaders took on the issue of vaccine inequity, challenging the view that intellectual property waivers could be the answer. 13.7 billion doses of vaccines have been delivered and 11…

Global Driven by increased demand from Big Pharma, mid-caps, and biotechs for outsourcing services, the USD 70 billion global contract research organisation (CRO) market is predicted to grow at a CAGR of between 11 and 12 percent over the next five to seven years, with differing estimates placing its total size…

Italy Organon Italy’s Alper Alptekin introduces the newly formed women’s health company, his priorities for the Italian affiliate, and how improvements in women’s health can improve gender equality and give women the ability to be stronger, more vocal, and more independent.   While Organon’s portfolio is meeting the needs of women,…

Global In 2022 global healthcare will continue to feel the effects of the pandemic and although COVID-19 has become less virulent, with the global death rate down to 0.4 percent from an initial peak of about three percent, new variants are still set to emerge this year. At the Economist Intelligence…

Italy Speaking exclusively to PharmaBoardroom, Pierluigi Antonelli outlines Angelini Pharma’s progress in transforming from a traditional, Italy-focused, and family-owned firm into a true European innovator. Antonelli outlines the potential impact of Angelini’s USD 960 million Arvelle acquisition, why he is optimistic about success in the challenging brain health space, and how…

Europe In an extensive recent PharmaBoardroom conversation, EMA Head of Advanced Therapies Ana-Hidalgo-Simon highlighted some of the most important trends around advanced therapy regulation in Europe. Hidalgo-Simon touched on why moderate growth in regulatory applications is a positive development for the EMA, how patient insights are being better incorporated into the…

Germany The latest from German pharma, including Bayer’s 2021 financial results, the country’s plan to spend $3.14 billion on vaccine capacity to cover Covid-19 outbreaks until 2029, and Boehringer Ingleheim’s case for broader use of its diabetes drug.   Bayer’s 2021 annual report: €44.1 billion revenue, Crop Science grows double digits,…

Europe Speaking exclusively to PharmaBoardroom, the EMA’s Head of Advanced Therapies Ana Hidalgo-Simon discusses steadily growing numbers of regulatory applications in the advanced therapy field, the vital importance of patient group insights, RWE collection and curation, hospital exemptions, manufacturing challenges, and more.   [Advanced] therapies are complex, difficult, and have a…

USA Ramona Sequeira, recently appointed chair of the PhRMA board of directors and president of Takeda’s US Business Unit and Global Portfolio Commercialization, gives her take on how the biopharma industry can do more to address the systemic inequities in US healthcare, including community-focused grant programs, clinical trial diversity initiatives, and…